In Tuesday’s Wall Street Journal, Alex Tabarok reviews a new book that provides yet another glimpse into the inner workings of our destructive regulatory state. The book, called Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances, chronicles the fight by a company called MELA Sciences to win approval from the FDA for a noninvasive method for detecting skin cancer. Initially enthusiastic about the product, the FDA later turned against the company when a new FDA director with a less favorable view of business came on board. The author of the book, who was the company’s CEO at the time (he has since retired), spent a year of his life at great personal cost fighting with the FDA before prevailing.